Skip to main content
. 2019 Dec 24;10(67):7142–7155. doi: 10.18632/oncotarget.27392

Figure 1. PRISMA.

Figure 1

* Eligibility Criteria 1) human subjects, 2) stage I-III NSCLC patients who underwent surgical resection, 3) at least 10 patients, 4) survival data for at least one of the predefined biomarkers or provided sufficient data to estimate survival, and 5) follow-up of at least 4 years.